183673-71-4

Basic information

• Product Name: 4-AMINO-1-BOC-PIPERIDINE-4-CARBOXYLIC ACID
• Synonyms: 4-amino-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-4-carboxylic acid;1-Boc-4-aminopiperidine-4-carboxylic acid≥ 98% (HPLC);L-Pip(Boc)-OH;BOC-PIC(4)(4-NH2)-OH;H-PIP(BOC)-OH;4-N-(TERT-BUTOXYCARBONYL)-1,1-AMINO-PIPERIDINYL CARBOXYLIC ACID;4-N-BOC-1,1-AMINO-PIPERIDINYL CARBOXYLIC ACID;4-N-Boc-1,1-Amino-piperidinyl carboxylic acid hydrate
• CAS NO: 183673-71-4
• Molecular Formula: C₁₁H₂₀N₂O₄
• Molecular Weight: 244.29
• Product Categories: pharmacetical;Piperidine;Amino Acids & Derivatives;Heterocycles
• Mol File: 183673-71-4.mol
• Article Data: 6

Chemical Properties

• Melting Point: 290°C
• Boiling Point: 387.21°C (rough estimate)
• Flash Point: 183.7 °C
• Appearance: white powder
• Density: 1.1583 (rough estimate)
• Vapor Pressure: 7.87E-07mmHg at 25°C
• Refractive Index: 1.4620 (estimate)
• Storage Temp.: 2-8°C
• Solubility: Methanol
• PKA: 2.15±0.20(Predicted)
• BRN: 7588844
• CAS DataBase Reference: 4-AMINO-1-BOC-PIPERIDINE-4-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-AMINO-1-BOC-PIPERIDINE-4-CARBOXYLIC ACID(183673-71-4)
• EPA Substance Registry System: 4-AMINO-1-BOC-PIPERIDINE-4-CARBOXYLIC ACID(183673-71-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 37/39-26-24/25
• WGK Germany: 3
• Hazardous Substances Data: 183673-71-4(Hazardous Substances Data)

Usage

Chemical Properties

White Powder

Uses

Different sources of media describe the Uses of 183673-71-4 differently. You can refer to the following data:
1. An a,a-Disubstituted Amino Acid for preparation of water-soluble highly helical peptides
2. An α,α-Disubstituted amino acid for preparation of water-soluble highly helical peptides.
3. Cyclic α,α-disubstituted amino acid for the preparation of water-soluble highly helical peptides.

InChI:InChI=1/C11H20N2O4/c1-10(2,3)17-9(16)13-6-4-11(12,5-7-13)8(14)15/h4-7,12H2,1-3H3,(H,14,15)

Upstream product

• 321997-89-1 methyl 1-tert-butyloxycarbonyl-4-aminopiperidin-4-carboxylate 
• 183673-70-3 tert-butyl 2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate 
• 40064-34-4 piperidine-4,4-diol hydrochloride 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 73390-11-1 4-piperidinone monohydrate 
• 13625-39-3 1,3,8-triaza-spiro[4.5]decan-2,4-dione 
• 41979-39-9 4-piperidone hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 183673-68-9 1-tert-butyloxycarbonylpiperidine-4-spiro-5'-(1',3'-bis(tertbutyloxy-carbonyl))hydantoin 

Downstream Products

• 495414-58-9 4-allyloxycarbonylamino-piperidine-1,4-dicarboxylic acid mono-tert-butyl ester 
• 287408-73-5 1-(tert-butoxycarbonyl)-4-({[4-(2-butynyloxy)phenyl]sulfonyl} amino)-4-piperidinecarboxylic acid 
• 203186-96-3 tert-butyl 4-amino-4-(hydroxymethyl)piperidine-1-carboxylate 

Relevant articles and documents

LIM KINASE INHIBITORS

The present invention relates to new kinase inhibitors, more specifically LIM Kinase inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and Prophylaxis of disease. In particular, the present invention relates to new LIMK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and Prophylaxis of disease. In addition, the invention relates to methods of treatment and use of said Compounds in the manufacture of a medicament for the application to a number of therapeutic indications including Ophthalmic and intestinal diseases.

A convenient preparation of an orthogonally protected c,c-disubstituted amino acid analog of lysine: 1-tert-butyloxycarbonyl-4-((9-fluorenylmethyloxycarbonyl)amino)-piperidine-4-carboxylic acid: [1,4-piperidinedicarboxylic acid, 4-[[(9H-fluoren-9-ylmethyloxy)carbonyl]amino]-, (1,1-dimethylethyl) ester]

-

Parallel solution- and solid-phase synthesis of spirohydantoin derivatives as neurokinin-1 receptor ligands

The combination of the 3,5-bis(trifluoromethyl)phenyl group with a spirohydantoin motive as a central scaffold was the basis for the design of a combinatorial library targeted towards the neurokinin-1 receptor. A solution- and solid-phase procedure is described and binding affinities of representative compounds presented.